Correlation Between Emergent Biosolutions and Esperion Therapeutics

Can any of the company-specific risk be diversified away by investing in both Emergent Biosolutions and Esperion Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Emergent Biosolutions and Esperion Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Emergent Biosolutions and Esperion Therapeutics, you can compare the effects of market volatilities on Emergent Biosolutions and Esperion Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Emergent Biosolutions with a short position of Esperion Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Emergent Biosolutions and Esperion Therapeutics.

Diversification Opportunities for Emergent Biosolutions and Esperion Therapeutics

0.77

Correlation Coefficient

Emergent Biosolutions  Esperion Therapeutics

Poor diversification

The 3 months correlation between Emergent and Esperion is 0.77. Overlapping area represents the amount of risk that can be diversified away by holding Emergent Biosolutions and Esperion Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Esperion Therapeutics and Emergent Biosolutions is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Emergent Biosolutions are associated (or correlated) with Esperion Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Esperion Therapeutics has no effect on the direction of Emergent Biosolutions i.e., Emergent Biosolutions and Esperion Therapeutics go up and down completely randomly.

Pair Corralation between Emergent Biosolutions and Esperion Therapeutics

Considering the 90-day investment horizon Emergent Biosolutions is expected to under-perform the Esperion Therapeutics. In addition to that, Emergent Biosolutions is 1.22 times more volatile than Esperion Therapeutics. It trades about -0.23 of its total potential returns per unit of risk. Esperion Therapeutics is currently generating about -0.14 per unit of volatility. If you would invest  215.00  in Esperion Therapeutics on December 29, 2024 and sell it today you would lose (65.00) from holding Esperion Therapeutics or give up 30.23% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Emergent Biosolutions  vs.  Esperion Therapeutics

Emergent Biosolutions

Risk-Adjusted Performance

Very Weak

Over the last 90 days Emergent Biosolutions has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental drivers remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Esperion Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Esperion Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Emergent Biosolutions and Esperion Therapeutics

The main advantage of trading using opposite Emergent Biosolutions and Esperion Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Emergent Biosolutions position performs unexpectedly, Esperion Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will offset losses from the drop in Esperion Therapeutics' long position.

The idea behind Emergent Biosolutions and Esperion Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.